Bill and Melinda Gates Foundation pledges USD287 million to HIV research

The Bill and Melinda Gates Foundation has announced a USD287 million (€227.6 million) donation to fund research into HIV vaccine development. A total of 16 grants will support large-scale collaborative projects involving more than 165 researchers in 19 countries worldwide, including researchers coming from nine European countries.

To date around 65 million people have been infected with HIV, and AIDS has killed more than 25 million people since it was first recognised in 1981, with three million dying each year. Sub-Saharan Africa remains the most affected region in the world, accounting for two thirds of all people living with HIV. While many different potential vaccines have been trialed over the years since the virus was first identified, scientists have struggled to develop an effective vaccine. This is because the HIV virus is able to mutate into different forms, thereby sidestepping antibodies raised by vaccines, to attack the immune system.

"An HIV vaccine is our best long-term hope for controlling the global AIDS epidemic, but it has proven to be a tremendously difficult scientific challenge," said Dr. Josй Esparza, senior advisor on HIV vaccines for the Gates Foundation. "We have all been frustrated by the slow pace of progress in HIV vaccine development, yet breakthroughs are achievable if we aggressively pursue scientific leads and work together in new ways."

The newly announced funding will go to support 11 vaccine discovery consortia, which will design vaccine candidates capable of eliciting effective neutralising antibodies to HIV. Research will also seek to improve current vaccine candidates so that they elicit stronger and more durable protective cellular immune responses.

In parallel to this, five central facilities will be established, including three laboratory networks for measuring the immune responses of vaccine candidates, a research specimen repository, and a data and statistical management centre. As a condition for receiving funding, the newly-funded vaccine discovery consortia have agreed to use the central facilities to test vaccine candidates, share information with other investigators, and compare results using standardised benchmarks. The aim here is to avoid fragmented research efforts.

In addition, the consortia will develop global access plans to help ensure that their discoveries will be accessible and affordable for developing countries.

"These projects bring a new level of creativity and intensity to bear on major scientific challenges facing HIV vaccine development," said Dr Nicholas Hellmann, acting director of the Gates Foundation's HIV, TB, and Reproductive Health programme. "Some of the vaccine concepts that will be pursued have been talked about for years, but have never been adequately studied. If successful, they could lead to entirely new paradigms for HIV vaccine development."

For further information, please visit:
http://www.gatesfoundation.org/default.htm

Copyright ©European Communities, 2006
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg – http://cordis.europa.eu.int. Access to CORDIS is currently available free-of-charge.

Most Popular Now

AI-Powered CRISPR could Lead to Faster G…

Stanford Medicine researchers have developed an artificial intelligence (AI) tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing “copilot” supported by AI to help...

Groundbreaking AI Aims to Speed Lifesavi…

To solve a problem, we have to see it clearly. Whether it’s an infection by a novel virus or memory-stealing plaques forming in the brains of Alzheimer’s patients, visualizing disease processes...

AI Spots Hidden Signs of Depression in S…

Depression is one of the most common mental health challenges, but its early signs are often overlooked. It is often linked to reduced facial expressivity. However, whether mild depression or...

ChatGPT 4o Therapeutic Chatbot 'Ama…

One of the first randomized controlled trials assessing the effectiveness of a large language model (LLM) chatbot 'Amanda' for relationship support shows that a single session of chatbot therapy...

AI Tools Help Predict Severe Asthma Risk…

Mayo Clinic researchers have developed artificial intelligence (AI) tools that help identify which children with asthma face the highest risk of serious asthma exacerbation and acute respiratory infections. The study...

AI Model Forecasts Disease Risk Decades …

Imagine a future where your medical history could help predict what health conditions you might face in the next two decades. Researchers have developed a generative AI model that uses...

AI Model Indicates Four out of Ten Breas…

A project at Lund University in Sweden has trained an AI model to identify breast cancer patients who could be spared from axillary surgery. The model analyses previously unutilised information...

AI Distinguishes Glioblastoma from Look-…

A Harvard Medical School–led research team has developed an AI tool that can reliably tell apart two look-alike cancers found in the brain but with different origins, behaviors, and treatments. The...

Overcoming the AI Applicability Crisis a…

Opinion Article by Harry Lykostratis, Chief Executive, Open Medical. The government’s 10 Year Health Plan makes a lot of the potential of AI-software to support clinical decision making, improve productivity, and...

Smart Device Uses AI and Bioelectronics …

As a wound heals, it goes through several stages: clotting to stop bleeding, immune system response, scabbing, and scarring. A wearable device called "a-Heal," designed by engineers at the University...

Dartford and Gravesham Implements Clinis…

Dartford and Gravesham NHS Trust has taken a significant step towards a more digital future by rolling out electronic test ordering using Clinisys ICE. The trust deployed the order communications...